Comparison of 48-week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens: a systematic review and network meta-analysis.

Gallien, S; Massetti, M; Flandre, P; Leleu, H; Descamps, D; Lazaro, E

Gallien, S; Massetti, M; Flandre, P; Leleu, H; Descamps, D; Lazaro, E.

Afiliação

Gallien S; Henri Mondor University Hospital, Créteil, France.
Massetti M; University of Paris-Est Créteil Val de Marne Medical School, Créteil, France.
Flandre P; Public Health Expertise, Paris, France.
Leleu H; INSERM Sorbonne University, UPMC University Paris 06, UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.
Descamps D; Public Health Expertise, Paris, France.
Lazaro E; Bichat Claude Bernard University Hospital, Paris, France.

HIV Med ; 2018 Jul 13.

Article em En | MEDLINE | ID: mdl-30004176

Palavras-chave

antiretroviral therapy; drug toxicity; elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination; network meta-analysis; nucleoside reverse transcriptase inhibitor-sparing regimen

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Systematic_reviews Idioma: En Revista: HIV Med Assunto da revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google